Role of 5-hydroxytryptamine 1A receptors in 6-hydroxydopmaine- induced catalepsy-like immobilization in rats: A therapeutic approach for treating catalepsy of Parkinson's disease

Iranian Journal of Pharmaceutical Research

Volumn 11, Issue 4, 2012, Pages 1175-1181

  Reyhani rad, Siamak ^a   Nayebi, Alireza Mohajjel ^b,c   Mahmoudi, Javad ^d   Samini, Morteza ^a   Babapour, Vahab ^a  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

6 hydroxydopamine; 8 OHDPAT; Catalepsy; NAN 190

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL) PIPERAZINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; OXIDOPAMINE; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALEPSY; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; HISTOLOGY; NERVE INJURY; NONHUMAN; PARKINSON DISEASE; RAT; SUBSTANTIA NIGRA PARS COMPACTA;

EID: 84871355835     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Mink JW. The basal ganglia: focused selection and inhibition of competing motor programs. Prog. Neurobiol. (1996) 50: 381-425.
2. Scholtissen B, Verhey FRJ, Steinbusch HWM and Leentjens AFG. Serotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data. J. Neural Transm. (2006) 113: 59-73.
3. Brown P and Gerfen CR. Plasticity within striatal direct pathway neurons after neonatal dopamine depletion is mediated through a novel functional coupling of serotonin 5-HT2 receptors to the ERK 1/2 map kinase pathway. J. Com. Neurol. (2006) 498: 415-430.
4. Vincenzo DM, Massimo P, Ennio E, Giuseppe C, Arcangelo B and Giuseppe DG. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders. Prog. Brain Res. (2008) 172: 423-463.
5. Knobelman DA, Kung HF and Lucki I. Regulation of extracellular concentrations of 5-hydroxytryptamine (5-HT) in mouse striatum by 5-HT1A and 5-HT1B receptors. J. Pharmacol. Exp. Ther. (2000) 292: 1111-1117.
6. Riad M, Garcia S, Watkins KC, Jodoin N, Doucet E, Langlois X, El-Mestinkawy S, Hamon M and dsescarries L. Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. J. Com. Neurol. (2000) 417: 181-194.
7. Bezard E, Gerlach I, Moratalla R, Gross CE and Jork R. 5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease. Neurobiol. Dis. (2006) 23: 77-86.
8. Dupre KB, Eskow KL, Negron G and Bishop C. The differential effects of 5-HT1A receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res. (2007) 1158: 135-143.
9. Gerber R, Alter CA and Leibman JM. Rotational behavior induced by 8-hydroxy-DPAT, a putative 5-HT1A agonist, in 6-hydroxydopamine-lesioned rats. Psychopharmacology (Berl) (1988) 94: 178-182.
10. Nayebi AM, Reyhani RS, Saberian M, Azimzadeh S and Samini M. Buspirone improves 6-hydroxydopamine- induced catalepsy through stimulation of nigral 5-HT1A receptors in rat. Pharmacol. Rep. (2010) 62: 258-264.
11. Nayebi AM and Sheidaei H. Buspirone improves haloperidol-induced Parkinson's disease in mice through 5-HT receptors. DARU (2010) 18: 41-15.
12. Hamon M, Fattaceini C M, Adrien J, Gallissot MC, Martin P and Gozlan H.J. Alterations of central serotonin and dopamine turnover in rats treated with ipsapirone and other 5 hydroxytryptamine1A agonists with potential anxiolytic properties. Pharmacol. Exp. Ther. (1988) 246: 745-752.
13. Arborelius L, Chergui K, Murase S, Nomikos G G, Hook BB, Chouvet G and Hacksell U. The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)- UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn Schmiedebergs Arch. Pharmacol. (1993) 347: 353-362.
14. Ichikawa J and Meltzer HY. R(+)-8-OH-DPAT, a serotonin 1A receptor agonist, potentiated S(-)- sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J. Pharmacol. Exp. Ther. (1999) 291: 1227-1232.
15. Nayebi AM. Hypothesis: A promising effect of 5-HT1A receptor agonists in alleviating motor symptoms of Parkinson's disease. Afr. J. Pharm. Pharmacol. (2010) 4: 289-290.
16. Paxinos G and Watson C. The Rat Brain in Stereotaxic Coordinates. Academic Press, Elsevier Inc. UK (2007).
17. Andreas S. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res. (2004) 318: 215-224.
18. Alex KD and Pehek EA. Pharmacologic mechanisms of seretonergic regulation of dopamine neurotransmission. Pharmacol. Ther. (2007) 113: 296-320.
19. Burnet PW, Eastwood SL, Lacey K and Harrison PJ. The distribution of 5-HT1A and 5-HT2B receptor mRNA in human brain. Brain Res. (1995) 676: 157-168.
20. Wright D E, Seroogy K B, Lundgren KH, Davis BM and Jennes L. Comparative localization of serotonin1A, 1C and 2 receptor subtype mRNA in rat brain. J. Comp. Neurol. (1995) 351: 357-373.
21. Harrington MA, Oksenberg D and Peroutka SJ. 5-Hydroxytryptamine 1A-receptors are linked to a G-- adenylate cyclase complex in rat hippocampus. Eur. J. Pharmacol. (1988) 154: 95-98.
22. Hedlund PB, Kelly L, Mazur C, Lovenberg T, Sutcliffe JG and Bonaventure P. 8-OH-DPAT acts on both 5-HT1A and 5-HT7 receptors to induce hypothermia in rodents. Eur. J. Pharmacol. (2004) 487: 125-132.
23. Susan HF, Rosalind C, Jonathan M and Brotchie. Parkinson's disease opportunities for novel therapeutics to reduce the problems of levodopa therapy. Prog. Brain Res. (2008) 172: 479-494.
24. Filip M and Bader M. Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system. Pharmacol. Rep. (2009) 61: 761-777.
25. Tunnicliff G. Molecular basis of buspirone's anxiolytic action. Pharmacol. Toxicol. (1991) 69: 149-156.
26. Forjaz MJ, Rodriguez BC and Martinez MP. On behalf of the Longitudinal Parkinson's Disease Patient Study (Estudio Longitudinal de Pacientes con Enfermedad de Parkinson-ELEP) Group: Rasch analysis of the hospital anxiety and depression scale in Parkinson's disease. Mov. Disord. (2008) 24: 525-531.
27. Imaki J, Mae Y, Shimizu S and Ohno Y. Therapeutic potential of alpha2 adrenoceptor antagonism for antipsychotic-induced extrapyramidal motor disorders. Neurosci. Lett. (2009) 454: 143-147.
28. Pires JGP, Bonikoski V and Futuro NHA. Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice. Braz. J. Med. Biol. Res. (2005) 38: 1867-1872.